Pediatrix director receives 472-share equity award

SANSONE GUY P reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

SANSONE GUY P reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group, Inc. reported that director Guy P. Sansone received an equity award of 472 shares of Common Stock on August 12, 2026. The restricted shares were granted under the Second Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027, bringing his post-grant direct holdings to 87,416 shares.

Insider Trade Summary

Grant/Award: 472 shares

Grant/Award 1 txn

Insider SANSONE GUY P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	472	$26.50	$13K

Holdings After Transaction: Common Stock — 87,416 shares (Direct)

Footnotes (1)

1. F1. Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027.

Key Figures

Restricted shares granted: 472 shares Grant price: $26.50 per share Holdings after transaction: 87,416 shares +1 more

4 metrics

Restricted shares granted 472 shares Grant of common stock to director on August 12, 2026

Grant price $26.50 per share Value per share for restricted stock award

Holdings after transaction 87,416 shares Director’s direct common stock holdings following the grant

Vesting date May 7, 2027 Date when the 472 restricted shares will vest

Key Terms

Restricted shares, Second Amended and Restated 2008 Incentive Compensation Plan, equity award

3 terms

Restricted shares financial

"Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Second Amended and Restated 2008 Incentive Compensation Plan financial

"granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan"

equity award financial

"reflecting an increase to the annual equity award. Shares will vest on May 7, 2027"

An equity award is a form of pay where a company gives employees, executives or other stakeholders the right to own or buy company shares—either immediately or after meeting certain conditions. Think of it like receiving slices of the company pie now or coupons to claim slices later; it matters to investors because it affects ownership dilution, executive incentives and reported compensation costs, and signals how management is being rewarded and retained.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pediatrix Medical Group (MD) report for Guy P. Sansone?

Pediatrix Medical Group reported that director Guy P. Sansone received a grant of 472 restricted common shares on August 12, 2026 as an equity award, increasing his direct holdings to 87,416 shares after the grant.

At what price were the 472 Pediatrix (MD) shares granted to Guy P. Sansone?

The 472 restricted shares were recorded at $26.50 per share. This value reflects the grant price used for the equity award under Pediatrix Medical Group’s Second Amended and Restated 2008 Incentive Compensation Plan.

When do Guy P. Sansone’s newly granted Pediatrix (MD) restricted shares vest?

The newly granted 472 restricted shares will vest on May 7, 2027. Until vesting, the shares are subject to restrictions as part of Pediatrix Medical Group’s equity compensation structure for its director.

How many Pediatrix (MD) shares does Guy P. Sansone hold after this Form 4 transaction?

Following the grant, director Guy P. Sansone directly holds 87,416 shares of Pediatrix Medical Group common stock. This figure includes the newly awarded 472 restricted shares reported in the Form 4 filing.

Was the Pediatrix (MD) equity grant to Guy P. Sansone made under a compensation plan?

Yes. The 472 restricted shares granted to Guy P. Sansone were awarded under Pediatrix Medical Group’s Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to his annual equity award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 05:01 PM Accepted by SEC EDGAR 08/14/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SANSONE GUY P

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FLORIDA 33323

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		A(1)		472	A	$26.5	87,416	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027.

	/s/ David Haddock, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)